About
Brett P. Monia is the CEO of Ionis Pharmaceuticals. He previously worked as a founding member of Isis and Senior Vice President of Antisense Drug Discovery. Dr. Monia is also the Franchise Leader for Programs in Oncology and Rare Genetic Diseases at Isis Pharmaceuticals. As head of Drug Discovery, Dr. Monia is responsible for establishing strategic directions for preclinical drug discovery research focused on RNA-directed therapeutic platforms, establishment and supervision of early clinical development strategies through clinical proof-of-concept, and coordinating research activities with clinical investigators, consultants, and with corporate partners. His contributions include research into the medicinal chemistry and mechanisms of action of oligonucleotide-based drugs in cell culture and in animals, and in the establishment of numerous preclinical and clinical programs in various therapeutic areas, including oncology, metabolic disease, inflammation, cardiovascular disease, and rar
Position in the VCSift Database
- • 2 investors at Ionis Pharmaceuticals are tracked.
- • 1,305 investors hold the Chief Executive Officer role in VCSift. Brett P. Monia is one of them.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
Contact Information
Find more investors like Brett
Search Investors